All News
Filter News
Found 241 articles
-
Bryn Pharma Appoints Pharmaceutical Industry Veteran Anne Clem Whitaker to Its Board of Directors
9/1/2021
Bryn Pharma, LLC today announced the appointment of Anne Clem Whitaker to its Board of Directors, effective immediately.
-
Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer
9/1/2021
Caladrius Biosciences, Inc. today announced the appointment of Dr. Kristen K. Buck as the Company’s Chief Medical Officer (“CMO”).
-
NJ Bio Welcomes Ilan Kaufthal as Senior Advisor and Pharmaceutical Executives, Ronald Gold, Steven Klosk, and Chetan Jain to its Board of Directors
8/25/2021
NJ Biopharmaceuticals LLC welcomed the appointments of Ilan Kaufthal as Senior Advisor, and Ronald Gold , Steven Klosk , and Chetan Jain to its Board of Directors.
-
Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business UpdateConference call begins today at 4:30 p.m. Eastern Time
8/5/2021
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and six months ended June 30, 2021.
-
Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time
7/29/2021
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended June 30, 2021, on Thursday, August 5, 2021, at 4:30 p.m. (ET).
-
Caladrius Biosciences to Present at Zooming with LD
7/22/2021
Caladrius Biosciences, Inc. today announced that its President and CEO, David J. Mazzo, PhD, will be presenting virtually at the Zooming with LD event on Thursday, July 29, 2021, at 10:00am Pacific Time/1:00pm Eastern Time.
-
Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney DiseaseFDA authorizes new IND for the study of CLBS201 in patients with reduced kidney function
6/22/2021
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that the U.S. Food and Drug Administration (“FDA”) has authorized its investigational new drug (“IND”) application for the study of CLBS201, a CD34+ cell therapy for the treatment of diabetic kidney disease (“DKD”).
-
Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit
6/17/2021
Caladrius Biosciences, Inc. today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius, will present at the Investor Forum at the World Stem Cell Summit to be held (virtually) June 14-18, 2021.
-
Stem Cell Therapy Market Increasing Awareness Related to the Stem Cells Therapy in Effective Disease Management
6/2/2021
The global stem cell therapy market is expected to reach US$ 5,129.66 Mn in 2027 from US$ 1,534.55 Mn in 2019.
-
Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021
6/1/2021
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events: NCVH Annual Conference (June 1-4, 2021)
-
Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
5/12/2021
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that it has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.
-
Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business UpdateConference call begins today at 4:30 p.m. Eastern Time
5/6/2021
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three months ended March 31, 2021.
-
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021
5/4/2021
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events:
-
Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time
4/29/2021
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended March 31, 2021 on Thursday, May 6, 2021 at 4:30 p.m. (ET).
-
Stem Cell and Regenerative Therapy Market: Cell Therapy Segment to Dominate Global Market
4/14/2021
Stem cells are body’s raw materials or cells from which all other cells with specialized functions are generated. These cells can be guided to become specific cells that regenerate and repair diseased or damaged tissues in patients suffering from various diseases.
-
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease
3/8/2021
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to the Company’s CD34+ cell therapy product, CLBS12, for the treatment of Buerger’s disease
-
Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
3/3/2021
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021.
-
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
2/25/2021
Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing
-
Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time
2/18/2021
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three and twelve months ended December 31, 2020 on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time